Member access

4-Traders Homepage  >  Shares  >  Amex  >  CEL-SCI Corporation       US1508374097

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine, is being developed as a potential therapeutic agent... 
More about the company
Financials ($)
Sales 2014 0,25 M
EBIT 2014 -24,8 M
Net income 2014 -22,9 M
Debt 2014 -
Yield 2014 -
Sales 2015 0,26 M
EBIT 2015 -26,9 M
Net income 2015 -27,0 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 245x
Capi. / Sales 2015 231x
Capitalization 60,1 M
More Financials
Latest news on CEL-SCI CORPORATION
1d ago CEL SCI : Announces Closing of Public Offering for Gross Proceeds of $6 Million
2d ago CEL SCI : Entry into a Material Definitive Agreement, Other Events, Financial St..
4d ago CEL SCI : NEW STORY CEL-SCI Corporation Prices $6 Million Public Offering of Com..
4d ago CEL SCI : NEW STORY CEL-SCI Corporation to Raise $1 Million in Registered Direct..
4d ago CEL SCI : to Raise $1 Million in Registered Direct Offering
4d ago CEL SCI : Prices $6 Million Public Offering of Common Stock and Warrants
5d ago CEL SCI : NEW STORY CEL-SCI Corporation Announces Proposed Public Offering of Co..
5d ago CEL SCI : Announces Proposed Public Offering of Common Stock and Warrants
10/15 CEL SCI : Enrolls 16 Patients in September in Its Phase III Immunotherapy Head a..
10/08 CEL SCI : Launches Its Phase III Immunotherapy Head and Neck Cancer Trial
10/03 CEL SCI : NEW STORY CEL-SCI Enrolls 16 Patients in September in Its Phase III Im..
10/03 CEL SCI : Enrolls 16 Patients in September in Its Phase III Immunotherapy Head a..
More news
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF